Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Finalizing scale-up production phase
Engaging with Contract Research Organizations to complete the technical dossier
Clinical trials expected to complete in late 2025 or early 2026
Potential classification as a Class III medical device
Product launch expected in the first or second quarter of 2026
Further updates on progress to follow in the coming months
CHICAGO, IL / ACCESS Newswire / February 11, 2025 / Cosmos Health Inc. ('Cosmos Health' or the 'Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it is entering the final stage of development for CCX0722, its innovative weight management solution. The Company is currently finalizing the scale-up production phase, paving the way for human clinical trials and targeting a market launch in the first or second quarter of 2026.
Building on the successful completion of pilot production and previous development milestones, Cosmos Health is now actively engaging with Contract Research Organizations (CROs) to complete the technical dossier, and clinical trials are set to be completed between the end of 2025 and the beginning of 2026. This strategic progress marks a critical step in positioning CCX0722 for regulatory submission and potential classification as a Class III medical device.
According to Grand View Research, the global weight management market was valued at $142.58 billion in 2022 and is expected to grow at a CAGR of 9.7% from 2023 to 2030, driven by the increasing prevalence of obesity and its associated health risks, including diabetes, hypertension, and orthopedic conditions.
As the Company nears regulatory submission and clinical validation, further updates on the progress of CCX0722 will be provided in the coming months.
Greg Siokas, CEO of Cosmos Health, stated: 'CCX0722 has demonstrated exceptional characteristics throughout its development, and we are now moving forward with clinical validation. We believe CCX0722 has the potential to be a transformative solution in tackling the growing obesity epidemic. Our team is fully committed to bringing this innovative biocompatible hydrogel to market, offering a safe and effective option for weight management. At Cosmos Health, we remain dedicated to delivering science-backed, high-impact solutions that address critical global health challenges.'
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words 'believes,' 'expects,' 'anticipates,' 'intends,' 'projects,' 'estimates,' 'plans' and similar expressions or future or conditional verbs such as 'will,' 'should,' 'would,' 'may' and 'could', are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
+44 207 0971 653
SOURCE: Cosmos Health Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Fortrea Names Anshul Thakral Chief Executive Officer
Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts: Hima Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
E-2 Hawkeye Replaces USAF E-3 Sentry, E-7 Cancelled In New Budget
A seismic shift has occurred in the Trump administration's new defense spending plan that is just emerging when it comes to the USAF's airborne early warning and control (AEW&C) predicament. The service's E-3 Sentry Airborne Warning and Control System (AWACS) aircraft are dwindling in number and rapidly aging into unsupportability. The proven and in-production E-7 Wedgetail, based on the Boeing 737 and serving with multiple allies, was supposed to bridge the gap between the E-3's retirement and pushing the sending part of the mission to space-based distributed satellite constellations. You can read all about this here. Now, if the administration gets its wish, that won't happen. The E-7 will be cancelled and the E-2D Hawkeye, currently flown by the U.S. Navy, will step in to fill the gap. This major turn of events came to light today as Secretary of Defense Pete Hegseth, Chairman of the Joint Chiefs of Staff U.S. Air Force Gen. John Caine, and Bryn Woollacott MacDonnell testified before the Senate Appropriations Committee. MacDonnell is Special Assistant to the Secretary of Defense and is currently performing the duties of the Under Secretary of Defense (Comptroller) and the Pentagon's Chief Financial Officer. In 2023, the USAF announced its intention to purchase E-7s, potentially as many as 26 of them, as replacements for a portion of the E-3 fleet. At the hearing today, the question of the current future of the USAF AEW&C force came from Sen. Lisa Murkowski late in the hearing. Murkowski is a Republican from Alaska, where fighters, tankers, and E-3 Sentry jets launch regularly to intercept foreign planes, primarily Russian fighters, bombers, and surveillance aircraft, over the vast arctic wilderness. Chinese H-6 missile carrier aircraft also appeared off Alaska last year for the first time, as part of a joint mission with Russia. Chinese air and naval presence in the region is only expected to grow in the future. China and Russia conduct joint air strategic patrol over Bering Sea on July 25. This marks the eighth air strategic patrol organized by the two militaries since from China PLA Air Force Weibo accounthttps:// — Ryan Chan 陳家翹 (@ryankakiuchan) July 25, 2024 With this in mind, just how big of an issue the age of the E-3 fleet has become was central to Murkowski's question. 'I have been concerned. We have E-3 capability up north, of course, but we were all counting on the E-7 Wedgetail coming our way. We're kind of limping along up north right now, which is unfortunate. And the budget proposes terminating the program. Again, the E-3 fleet [is] barely operational now, and I understand the intent to shift towards the space-based – you call it the 'air moving target indicators' – but my concern is that you've got a situation where you're not going to be able to use more duct tape to hold things together until you put this system in place. And, so, how we maintain that level of operational readiness and coverage, I'm not sure how you make it.' 'You know, the E-3 and the E-3 community have been really important to us for a long, long time, and I'll defer to the Comptroller, but I you know the Department has a bridging strategy through investing in some additional airborne platforms in order to gap fill while the space-based capabilities come online,' Kane replied in response to the senator's question. This is where the E-2D comes in. MacDonnell then added, 'Ma'am, we do have in the budget $150 million in FY26 [Fiscal Year 2026] for a joint expeditionary E-2D unit with five dedicated E-2Ds, and the budget also funds for additional E-2Ds to fill the near-term gap at $1.4 billion.' Currently, the only branch of the U.S. military that operates the E-2D is the U.S. Navy. The Alaskan senator then inquired, 'Can you tell me, will that have implications for what we're seeing up north in Alaska?' 'The answer is yes. I would. I would file this entire discussion under difficult choices that we have to make. But you know, the E-7, in particular, is sort of late, more expensive and 'gold plated,' and so filling the gap, and then shifting to space-based ISR [intelligence, surveillance, and reconnaissance] is a portion of how we think we can do it best, considering all the challenges,' Hegseth responded. At a separate hearing before the House Appropriations Committee yesterday, Hegsteth had also described the Wedgetail as an example of a capability that is 'not survivable in the modern battlefield' and mentioned broad plans 'to fund existing platforms that are there more robustly and make sure they're modernized.' An annual assessment of high-profile U.S. military procurement programs from the Government Accountability Office (GAO), a Congressional watchdog, which was released today, offers additional insight into issues with the USAF's effort to acquire E-7s. The original plan was to acquire a pair of production representative prototype (or RP) aircraft ahead of production of examples in a finalized configuration, starting this year. The service had then expected to reach initial operational capability with the Wedgetail in 2027. 'Air Force officials said that they now plan to begin production by the second quarter of fiscal year 2026 before completing the E-7A RP MTA [Middle Tier Acquisition] rapid prototyping effort by initiating a separate, concurrent program on the major capability acquisition pathway,' according to GAO. 'They said that it was necessary to begin production concurrently with the E-7A RP rapid prototyping effort to offset the lead time associated with the build and subsequent modification of the aircraft.' 'The program definitized its contract with Boeing since our last assessment. After the contract was definitized, Boeing delayed the first flight test by 9 months to May 2027,' the report adds. 'According to Air Force officials, the delay was due to a late-breaking, required critical security architecture change that affected the procurement of parts, qualification testing, and modification of the airframe.' 'The program stated that the Air Force definitized the MTA rapid prototyping effort contract in August 2024 to deliver two operationally capable E-7A prototype aircraft in fiscal year 2028,' GAO's new assessment further notes. 'The program added that the total acquisition cost increase of 33 percent resulted from updated methodologies to include additional scope related to non-recurring engineering, with the primary drivers being software and air vehicle subsystems.' Last year, the Air Force had been very open about the difficulties it was having finalizing a contract with Boeing for the RP jets. The two parties ended up agreeing on a deal valued at nearly $2.6 billion. A contracting notice the service put out earlier this year also pointed to significant expected differences between the RP aircraft and the full production examples, including the possibility of a new radar. Existing versions of the E-7 in service elsewhere globally today are equipped with Northrop Grumman's Multi-Role Electronically Scanned Array (MESA) radar. The USAF's move to drop the E-7 and leverage the E-2D, which is already in the Pentagon's stable, prompts many questions. For instance, just how many of these aircraft will the USAF end up with? As of 2024, the USAF's E-3 fleet stood at 16 aircraft. Above all else, there are major capability trades here. The Hawkeye is a much smaller aircraft than both the Sentry and the Wedgetail. It is extremely capable, but it is also optimized to exist within the confines of carrier operations. The crew size is just five individuals. This limits the amount of shear manpower to perform highly complex operations and other tasks beyond traditional AEW&C. The E-2 also has less range and is far slower than both the E-3 and E-7. This means longer transit times, and the aircraft doesn't fit in as seamlessly with the jet-centric operations for the counter-air mission the service currently enjoys. The E-2D's AN/APY-9 radar from Lockheed Martin is hugely capable, but many of its other advanced data fusion and relay systems are unique to the Navy. These systems would either be stripped or just left unused for USAF-focused operations. It's also possible that other systems will replace them, but this will cost money and take time to integrate and field. Hawkeyes, being turboprop aircraft, also operate at lower altitudes, giving their radar, radio systems, and electronic surveillance suites reduced line-of-sight, limiting their range and fidelity at distance for some targets and surveillance application, in some cases. Then there is the aerial refueling issue. The E-2D has gained this ability relatively recently, which expands its endurance. Typical missions can now last over seven hours. However, the aircraft uses the Navy-preferred probe-and-drogue refueling method, not the boom and receptacle one favored by the USAF. The USAF's KC-46 tankers do have a hose and drogue system and some of the service's KC-135Rs have podded hose and drogue systems. Otherwise, they require a basket attachment to their boom, often called the 'Iron Maiden' or 'Wrecking Ball,' due to its rigid metal frame and potential to smack into and damage airframes. This system makes the KC-135R useless for refueling receptacle-equipped aircraft when it is fitted. The E-2D also refuels lower-and-slower than jet aircraft. All these issues are not 'show-stoppers,' but they are ones that will impact operational planning and flexibility. The E-2D, being already a highly upgraded and a much smaller airframe, also lacks the same capacity for future expansion compared to the E-7. This could include adding more personnel for various non-traditional functions, including using its advanced radar to scan the surface more extensively or for unique battle management needs, such as controlling future drone swarms, or even for more extensive passive intelligence collection and exploitation and data fusion operations. High-bandwidth datalinks can possibly make up for some of the manpower differentials, allowing folks on the ground to execute critical functions in near real time as part of a distributed crew arrangement, but there are downfalls to this concept, as well. On the other hand, having commonality with the Navy's AEW&C aircraft should help reduce costs for both services and accelerate the type's entry into USAF service. It could also benefit the future evolution of the E-2D as more money will be flowing into the program. It's also a very capable and well-proven platform, lowering risk. Above all else, joint service E-2Ds could be absolutely critical to the USAF's Agile Combat Employment (ACE) combat doctrine that will see its forces distributed to remote forward locales and constantly in motion. The E-2D's turboprop performance, robust landing gear, and arrested landing capabilities mean it can be pushed far forward to very austere operating locations with limited runway length. And it can do this without sacrificing the quality of the data it collects or the efficacy of its use as a battle manager. This is something a 707 or 737 platform simply cannot match and could prove decisive in a major peer-state contingency. TWZ highlighted these exact benefits after U.S. Central Command (CENTCOM) released a video last year showing a Navy Hawkeye refueling from a USAF HC-130J Combat King II combat search and rescue aircraft, which can act as a probe-and-drogue tanker, primarily for helicopters and Osprey tiltrotors. A @USNavy E-2D refuels inflight from an @usairforce HC-130 over the U.S. Central Command area of responsibility. — U.S. Central Command (@CENTCOM) August 6, 2024 While the USAF's move away from the E-7 is certainly surprising, and it will result in shortfalls in some areas, it also unlocks new capabilities, some of which are arguably more applicable to tomorrow's wars. It also buys down additional risk, which is looming very large as it isn't clear at this time, at least publicly, how far along the Pentagon's persistent space-based aircraft sensing constellation development actually is. All of this still has to make it through congressional approval, which could be a challenge considering the special interests involved. But as it sits now, the flying service is pivoting big once again when it comes to its increasingly dire AEW&C needs. Contact the author: Tyler@
Yahoo
23 minutes ago
- Yahoo
Bonterra Resources Announces Election Results of its 2025 Annual General Meeting
Val-d'Or, Quebec--(Newsfile Corp. - June 11, 2025) - Bonterra Resources Inc. (TSXV: BTR) (OTCQX: BONXF) (FSE: 9BR2) ("Bonterra" or the "Company") announces election results of its 2025 annual general meeting held on June 11, 2025 ("2025 AGM"), representing its fiscal year ended 2024. Bonterra is pleased to announce that shareholders have approved all matters voted on at the 2025 AGM, including: (i) to set the number of directors at seven (7); (ii) to re-elect Messrs. Cesar Gonzalez, Marc-André Pelletier, Normand Champigny, Paul Jacobi, Matt Houk, Lesley Antoun and Peter O'Malley as Directors; (iii) to appoint the Crowe MacKay LLP, as auditors of the Company for the ensuing year and to authorize the directors to fix their remuneration; and (iv) to consider and, if deemed advisable, adopt with or without variation, an ordinary resolution to approve the Company's Omnibus Equity Incentive Compensation Plan. Details in respect of such matters were provided in the Company's management information circular dated May 6, 2025. A total of 77,193,201 common shares were voted at the Meeting, representing approximately 46% of the common shares issued and outstanding as of the record date. Results from the vote are presented in the table below: Report on Proxies To view an enhanced version of this graphic, please visit: About Bonterra Resources is a Canadian gold exploration company with a portfolio of advanced exploration assets anchored by a central milling facility in Quebec, Canada. The Company's assets include the Gladiator, Barry, Moroy, and Bachelor gold deposits, which collectively hold 1.24 million ounces in Measured and Indicated categories and 1.78 million ounces in the Inferred category. In November 2023, the Company entered into a earn-in and joint venture agreement with Osisko Mining Inc. for the Urban-Barry properties (the "JV Agreement"), which include the Gladiator and Barry deposits. In October 2024, Gold Fields Ltd completed the acquisition of Osisko Mining for C$2.16 billion. Gold Fields is now the counterparty to the JV Agreement and can continue to earn a 70% interest in the joint venture by incurring C$30 million in work expenditures until November 2026 (including expenditures incurred by Osisko Mining prior to October 2024). This strategic transaction highlights Bonterra's dedication to advancing its exploration assets, marking a significant step towards development. FOR ADDITIONAL INFORMATION Marc-André Pelletier, President & CEOir@ 2872 Sullivan Road, Suite 2, Val d'Or, Quebec J9P 0B9819-825-8678 | Website: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Caution regarding forward-looking statements This press release contains "forward-looking information" that is based on Bonterra's current expectations, estimates, forecasts, and projections. This forward-looking information includes, among other things, statements with respect to the earn-in and joint venture agreement with Osisko Mining announced on November 28, 2023. The words "will", "anticipated", "plans" or other similar words and phrases are intended to identify forward-looking information. This forward-looking information includes namely information with respect to the planned exploration programs and the potential growth in mineral resources. Exploration results that include drill results on wide spacing may not be indicative of the occurrence of a mineral deposit and such results do not provide assurance that further work will establish sufficient grade, continuity, metallurgical characteristics, and economic potential to be classed as a category of mineral resource. The potential quantities and grades of drilling targets are conceptual in nature and, there has been insufficient exploration to define a mineral resource, and it is uncertain if further exploration will result in the targets being delineated as mineral resources. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause Bonterra's actual results, level of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information. Such factors include but are not limited to: uncertainties related exploration and development; the ability to raise sufficient capital to fund exploration and development; changes in economic conditions or financial markets, environmental and other judicial, regulatory, political, and competitive developments; technological or operational difficulties or inability to obtain permits encountered in connection with exploration activities; and labour relations matters. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. To view the source version of this press release, please visit Sign in to access your portfolio
